6 Major FDA Decisions And Biopharma Catalysts Coming In January And February
1/9/2017 8:11:34 AM
Companies that reside within the biotech and pharmaceutical industries are subject to a sizable amount of risk in regards to their drug candidates passing clinical trials and gaining regulatory approval. But with the risk of failure, which could spell disaster for a stock, comes great reward as well. Some companies can see a massive upside just from winning a single mid-stage trial or even achieving as much as a Fast Track designation from the U.S. Food and Drug Administration (FDA).
comments powered by